​

Sarepta Therapeutics (SRPT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SRPT Stock Forecast

Sarepta Therapeutics stock forecast is as follows: an average price target of $184.00 (represents a 59.38% upside from SRPT’s last price of $115.45) and a rating consensus of 'Buy', based on 21 wall street analysts offering a 1-year stock forecast.

SRPT Price Target

The average price target for Sarepta Therapeutics (SRPT) is $184.00 based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $203.00 to $165.00. This represents a potential 59.38% upside from SRPT's last price of $115.45.

SRPT Analyst Ratings

Buy

According to 21 Wall Street analysts, Sarepta Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SRPT stock is 0 'Strong Buy' (0.00%), 16 'Buy' (76.19%), 4 'Hold' (19.05%), 1 'Sell' (4.76%), and 0 'Strong Sell' (0.00%).

Sarepta Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 27, 2024Biren AminPiper Sandler$182.00$136.8732.98%57.64%
Nov 27, 2024Gil BlumNeedham$202.00$136.8747.59%74.97%
Nov 07, 2024Brian SkorneyRobert W. Baird$193.00$124.9554.46%67.17%
Nov 07, 2024Kristen KluskaCantor Fitzgerald$167.00$124.9533.65%44.65%
Oct 21, 2024Andrew TsaiJefferies$165.00$127.0829.84%42.92%
Aug 08, 2024Gavin Clark-GartnerEvercore ISI$179.00$136.4031.23%55.05%
Aug 08, 2024Biren AminPiper Sandler$200.00$140.0642.80%73.24%
Aug 08, 2024Gena WangBarclays$203.00$140.0644.94%75.83%
Aug 08, 2024Brian AbrahamsRBC Capital$181.00$140.0629.23%56.78%
Jul 29, 2024Brian AbrahamsRBC Capital$182.00$147.8823.07%57.64%
Jun 27, 2024Kostas BiliourisBMO Capital$200.00$154.7929.21%73.24%
Jun 26, 2024Biren AminPiper Sandler$205.00$156.9130.65%77.57%
Jun 24, 2024Gavin Clark-GartnerEvercore ISI$185.00$160.7215.11%60.24%
Jun 24, 2024Uy EarMizuho Securities$200.00$165.1321.12%73.24%
Jun 21, 2024Brian SkorneyRobert W. Baird$200.00$171.3516.72%73.24%
Jun 13, 2024Brian SkorneyRobert W. Baird$170.00$124.0037.10%47.25%
Jun 13, 2024Biren AminPiper Sandler$157.00$119.9830.86%35.99%
Jun 13, 2024Gena WangBarclays$185.00$119.9854.19%60.24%
Jun 07, 2024Kostas BiliourisBMO Capital$170.00$117.4444.75%47.25%
May 28, 2024Brian AbrahamsRBC Capital$142.00$123.4615.02%23.00%
May 20, 2024Brian AbrahamsRBC Capital$157.00$130.7020.12%35.99%
May 17, 2024Uy EarMizuho Securities$179.00$132.7434.85%55.05%
May 14, 2024Hartaj SinghOppenheimer$180.00$131.7036.67%55.91%
May 06, 2024Matthew HarrisonMorgan Stanley$165.00$135.0422.19%42.92%
May 02, 2024Brian AbrahamsRBC Capital$141.00$130.907.72%22.13%
Mar 01, 2023Matthew HarrisonMorgan Stanley$187.00$145.0128.96%61.97%
Jan 10, 2023Credit Suisse$114.00$117.53-3.00%-1.26%
Jan 10, 2023Needham$160.00$117.5336.14%38.59%
Dec 22, 2022BTIG$160.00$132.1321.09%38.59%
Dec 16, 2022UBS$158.00$123.5627.87%36.86%
Nov 03, 2022Gil BlumNeedham$158.00$105.0150.46%36.86%
Sep 08, 2022Morgan Stanley$135.00$116.5715.81%16.93%
Aug 15, 2022Hartaj SinghOppenheimer$150.00$109.0037.61%29.93%
Aug 03, 2022Morgan Stanley$100.00$95.205.04%-13.38%
Jul 29, 2022Needham$162.00$93.9672.41%40.32%
Jul 15, 2022Morgan Stanley$80.00$84.04-4.81%-30.71%
May 24, 2022Goldman Sachs$155.00$68.84125.16%34.26%
Mar 02, 2022Zhiqiang ShuBerenberg Bank$94.00$79.5618.15%-18.58%
Mar 02, 2022Gil BlumNeedham$150.00$79.5688.54%29.93%
Jan 10, 2022Uy EarMizuho Securities$160.00$76.15110.11%38.59%
Jan 05, 2022Yun ZhongBTIG$125.00$84.0948.65%8.27%
Jan 04, 2022Hartaj SinghOppenheimer$125.00$89.1640.20%8.27%
Oct 15, 2021Judah FrommerCredit Suisse$95.00$84.1912.84%-17.71%

The latest Sarepta Therapeutics stock forecast, released on Nov 27, 2024 by Biren Amin from Piper Sandler, set a price target of $182.00, which represents a 32.98% increase from the stock price at the time of the forecast ($136.87), and a 57.64% increase from SRPT last price ($115.45).

Sarepta Therapeutics Price Target by Period

1M3M12M
# Anlaysts-425
Avg Price Target-$186.00$179.60
Last Closing Price$115.45$115.45$115.45
Upside/Downside-100.00%61.11%55.57%

In the current month, the average price target of Sarepta Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Sarepta Therapeutics's last price of $115.45. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 02, 2024BMO CapitalOutperformOutperformHold
Nov 27, 2024Piper SandlerOverweightOverweightHold
Nov 27, 2024NeedhamBuyBuyHold
Nov 07, 2024Cantor FitzgeraldNeutralOverweightUpgrade
Oct 21, 2024Raymond JamesUnderperformUnderperformHold
Oct 21, 2024RBC CapitalBuyBuyHold
Oct 21, 2024JefferiesBuyInitialise
Oct 04, 2024Piper SandlerUnderperformUnderperformHold
Oct 04, 2024RBC CapitalNeutralNeutralHold
Sep 23, 2024Cowen & Co.BuyBuyHold
Sep 11, 2024BMO CapitalOutperformOutperformHold
Sep 06, 2024Sandler O'NeilUnderperformUnderperformHold
Sep 06, 2024Sandler O'NeillSector PerformSector PerformHold
Aug 08, 2024Evercore ISIOutperformUpgrade
Aug 08, 2024Piper SandlerOverweightOverweightHold
Aug 08, 2024BarclaysOverweightOverweightHold
Aug 08, 2024RBC CapitalOutperformOutperformHold
Jul 29, 2024Sandler O'NeilUnderperformUnderperformHold
Jul 29, 2024Sandler O'NeillSector PerformSector PerformHold
Jul 29, 2024RBC CapitalSector PerformOutperformUpgrade
Jul 01, 2024Sandler O'NeillSector PerformSector PerformHold
Jun 26, 2024CitigroupBuyNeutralDowngrade
Jun 21, 2024Cowen & Co.BuyBuyHold
Jun 21, 2024NeedhamBuyBuyHold
Jun 21, 2024Goldman SachsBuyBuyHold
Jun 20, 2024Morgan StanleyOverweightOverweightHold
Jun 14, 2024Piper SandlerUnderperformUnderperformHold
Jun 14, 2024RBC CapitalSector PerformSector PerformHold
Jun 13, 2024CitigroupBuyBuyHold
Jun 13, 2024Piper SandlerOverweightOverweightHold
Jun 13, 2024BarclaysOverweightOverweightHold
Jun 07, 2024BMO CapitalOutperformOutperformHold
May 31, 2024Piper SandlerOverweightInitialise
May 20, 2024UBSBuyBuyHold
May 14, 2024OppenheimerBuyOutperformUpgrade
May 06, 2024Morgan StanleyOverweightOverweightHold
May 02, 2024WedbushBuyBuyHold
May 02, 2024RBC CapitalSector PerformSector PerformHold
Apr 04, 2024CitigroupBuyBuyHold
Feb 15, 2024WedbushBuyBuyHold
Jan 10, 2024RBC CapitalUnderperformUnderperformHold
Jan 10, 2024WedbushBuyBuyHold
Oct 31, 2023William BlairMarket PerformMarket PerformHold
Oct 31, 2023Cantor FitzgeraldNeutralDowngrade
Apr 13, 2023William BlairOutperformOutperformHold
Mar 22, 2023Cowen & Co.OutperformOutperformHold
Mar 17, 2023NeedhamBuyBuyHold
Mar 09, 2023OppenheimerOutperformBuyUpgrade
Mar 01, 2023GuggenheimBuyInitialise
Mar 01, 2023Morgan StanleyEqual-WeightOverweightUpgrade
Jan 10, 2023Credit SuisseNeutralNeutralHold
Jan 10, 2023NeedhamBuyBuyHold
Dec 22, 2022BTIGBuyBuyHold
Dec 16, 2022UBSBuyUpgrade
Sep 08, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Aug 15, 2022OppenheimerOutperformOutperformHold
Jul 29, 2022NeedhamBuyBuyHold
Jul 15, 2022Morgan StanleyEqual-WeightEqual-WeightHold
May 24, 2022Goldman SachsBuyBuyHold
Apr 26, 2022NeedhamBuyBuyHold
Apr 26, 2022Zacks Investment ResearchSellDowngrade

Sarepta Therapeutics's last stock rating was published by BMO Capital on Dec 02, 2024. The company gave SRPT a "Outperform" rating, the same as its previous rate.

Sarepta Therapeutics Financial Forecast

Sarepta Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$396.78M$331.82M$261.24M$253.50M$258.43M$230.27M$233.49M$210.83M$201.46M$189.41M$164.09M$146.93M$145.14M$143.92M$137.36M$113.67M$100.11M$99.04M
Avg Forecast$985.83M$965.09M$923.37M$901.53M$873.41M$815.42M$770.56M$698.87M$625.84M$407.17M$394.38M$379.52M$387.18M$285.33M$255.99M$241.92M$250.40M$234.52M$220.81M$206.43M$197.97M$178.89M$167.07M$145.81M$150.38M$137.76M$115.66M$234.11M$98.80M$98.48M
High Forecast$1.10B$1.08B$1.03B$1.01B$975.13M$910.39M$860.30M$810.10M$662.32M$407.41M$394.38M$379.52M$393.32M$285.71M$285.81M$270.09M$276.59M$234.52M$220.81M$206.43M$197.97M$178.89M$167.07M$145.81M$150.38M$137.76M$115.66M$234.11M$98.80M$98.48M
Low Forecast$785.22M$768.70M$735.47M$718.07M$695.68M$649.49M$613.76M$464.03M$569.10M$406.94M$394.38M$379.52M$366.05M$284.96M$203.90M$192.69M$208.60M$234.52M$220.81M$206.43M$197.97M$178.89M$167.07M$145.81M$150.38M$137.76M$115.66M$234.11M$98.80M$98.48M
# Analysts5454434810966136665551112111091377986
Surprise %------------1.02%1.16%1.02%1.05%1.03%0.98%1.06%1.02%1.02%1.06%0.98%1.01%0.97%1.04%1.19%0.49%1.01%1.01%

Sarepta Therapeutics's average Quarter revenue forecast for Mar 24 based on 6 analysts is $379.52M, with a low forecast of $379.52M, and a high forecast of $379.52M. SRPT's average Quarter revenue forecast represents a -4.35% decrease compared to the company's last Quarter revenue of $396.78M (Dec 23).

Sarepta Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts5454434810966136665551112111091377986
EBITDA------------$-28.46M$-20.84M$-133.52M$-107.75M$-81.49M$-112.24M$-202.18M$-77.63M$-95.70M$-21.42M$-57.48M$-142.81M$-162.47M$-175.90M$-130.61M$2.77M$-218.40M$-110.31M
Avg Forecast$-641.31M$-627.83M$-600.68M$-586.48M$-568.18M$-530.46M$-501.28M$-454.64M$-407.13M$-264.88M$-256.56M$-94.97M$-251.87M$-185.62M$-166.53M$-101.57M$-125.63M$-154.32M$-145.30M$-108.63M$-130.27M$-117.71M$-109.94M$-116.19M$-98.95M$-90.65M$-76.11M$4.68M$-65.01M$-64.80M
High Forecast$-510.81M$-500.07M$-478.45M$-467.13M$-452.56M$-422.51M$-399.27M$-301.87M$-370.22M$-264.73M$-256.56M$-75.98M$-238.13M$-185.37M$-132.64M$-81.26M$-100.51M$-154.32M$-145.30M$-86.91M$-130.27M$-117.71M$-109.94M$-92.95M$-98.95M$-90.65M$-76.11M$5.61M$-65.01M$-64.80M
Low Forecast$-716.00M$-700.94M$-670.64M$-654.78M$-634.35M$-592.24M$-559.65M$-526.99M$-430.86M$-265.03M$-256.56M$-113.96M$-255.87M$-185.87M$-185.93M$-121.89M$-150.76M$-154.32M$-145.30M$-130.36M$-130.27M$-117.71M$-109.94M$-139.42M$-98.95M$-90.65M$-76.11M$3.74M$-65.01M$-64.80M
Surprise %------------0.11%0.11%0.80%1.06%0.65%0.73%1.39%0.71%0.73%0.18%0.52%1.23%1.64%1.94%1.72%0.59%3.36%1.70%

7 analysts predict SRPT's average Quarter EBITDA for Jun 20 to be $-76.11M, with a high of $-76.11M and a low of $-76.11M. This is -2850.54% lower than Sarepta Therapeutics's previous annual EBITDA (Mar 20) of $2.77M.

Sarepta Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts5454434810966136665551112111091377986
Net Income------------$45.66M$-40.94M$-23.94M$-516.75M$-109.24M$-257.74M$-231.48M$-105.03M$-121.98M$-48.14M$-81.41M$-167.25M$-189.32M$-196.50M$-150.82M$-17.49M$-235.70M$-126.33M
Avg Forecast$368.84M$362.04M$347.18M$328.29M$317.19M$291.75M$284.94M$255.64M$191.48M$-7.58M$-13.01M$-111.22M$6.92M$-122.86M$-178.48M$-118.95M$-135.59M$-115.84M$-104.87M$-127.22M$-118.75M$-169.03M$-122.84M$-136.07M$-170.36M$-161.91M$-163.19M$-29.56M$-170.84M$-128.01M
High Forecast$424.68M$416.85M$399.74M$378.00M$365.21M$335.92M$328.08M$574.60M$256.07M$-5.58M$-9.57M$-88.98M$237.75M$-90.36M$-131.26M$-95.16M$-108.47M$-115.84M$-104.87M$-101.78M$-118.75M$-169.03M$-122.84M$-108.85M$-170.36M$-161.91M$-163.19M$-23.65M$-170.84M$-128.01M
Low Forecast$271.26M$266.26M$255.34M$241.45M$233.28M$214.57M$209.56M$-508.93M$113.30M$-8.73M$-14.97M$-133.47M$-92.33M$-141.46M$-205.50M$-142.74M$-162.71M$-115.84M$-104.87M$-152.67M$-118.75M$-169.03M$-122.84M$-163.28M$-170.36M$-161.91M$-163.19M$-35.47M$-170.84M$-128.01M
Surprise %------------6.59%0.33%0.13%4.34%0.81%2.23%2.21%0.83%1.03%0.28%0.66%1.23%1.11%1.21%0.92%0.59%1.38%0.99%

Sarepta Therapeutics's average Quarter net income forecast for Mar 24 is $-111.22M, with a range of $-133.47M to $-88.98M. SRPT's average Quarter net income forecast represents a -343.61% decrease compared to the company's last Quarter net income of $45.66M (Dec 23).

Sarepta Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts5454434810966136665551112111091377986
SG&A------------$131.70M$120.89M$118.56M$110.71M$120.48M$104.79M$154.32M$71.84M$78.06M$61.13M$72.35M$71.13M$86.21M$75.54M$73.85M$82.93M$81.62M$75.64M
Avg Forecast$514.71M$503.88M$482.10M$470.69M$456.01M$425.74M$402.31M$364.88M$326.75M$212.59M$205.91M$47.30M$202.15M$148.97M$133.66M$50.59M$46.95M$122.44M$115.29M$54.11M$103.36M$93.40M$87.23M$57.87M$78.51M$71.93M$60.39M$140.15M$51.59M$51.42M
High Forecast$574.65M$562.56M$538.24M$525.51M$509.12M$475.32M$449.17M$422.95M$345.80M$212.71M$205.91M$56.76M$205.36M$149.17M$149.22M$60.71M$56.34M$122.44M$115.29M$64.93M$103.36M$93.40M$87.23M$69.44M$78.51M$71.93M$60.39M$168.18M$51.59M$51.42M
Low Forecast$409.97M$401.34M$383.99M$374.91M$363.22M$339.10M$320.44M$242.27M$297.13M$212.47M$205.91M$37.84M$191.12M$148.78M$106.46M$40.47M$37.56M$122.44M$115.29M$43.29M$103.36M$93.40M$87.23M$46.30M$78.51M$71.93M$60.39M$112.12M$51.59M$51.42M
Surprise %------------0.65%0.81%0.89%2.19%2.57%0.86%1.34%1.33%0.76%0.65%0.83%1.23%1.10%1.05%1.22%0.59%1.58%1.47%

Sarepta Therapeutics's average Quarter SG&A projection for Mar 24 is $47.30M, based on 6 Wall Street analysts, with a range of $37.84M to $56.76M. The forecast indicates a -64.08% fall compared to SRPT last annual SG&A of $131.70M (Dec 23).

Sarepta Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts5454434810966136665551112111091377986
EPS------------$0.79$-0.46$-0.27$-5.86$-1.34$-2.94$-2.65$-1.20$-1.53$-0.60$-1.02$-2.10$-2.41$-2.50$-1.93$-0.23$-3.08$-1.70
Avg Forecast$3.67$3.60$3.46$3.27$3.16$2.90$2.84$2.54$1.91$-0.08$-0.13$0.01$0.07$-1.22$-1.78$-1.29$-1.47$-1.22$-1.11$-1.31$-1.26$-1.79$-1.30$-1.83$-1.80$-1.71$-1.72$-1.92$-1.81$-1.35
High Forecast$4.23$4.15$3.98$3.76$3.64$3.34$3.27$5.72$2.55$-0.06$-0.10$0.01$2.37$-0.90$-1.31$-0.95$-1.15$-1.22$-1.11$-1.31$-1.26$-1.79$-1.30$-1.83$-1.80$-1.71$-1.72$-1.92$-1.81$-1.35
Low Forecast$2.70$2.65$2.54$2.40$2.32$2.14$2.09$-5.07$1.13$-0.09$-0.15$0.01$-0.92$-1.41$-2.05$-1.49$-1.67$-1.22$-1.11$-1.31$-1.26$-1.79$-1.30$-1.83$-1.80$-1.71$-1.72$-1.92$-1.81$-1.35
Surprise %------------11.46%0.38%0.15%4.53%0.91%2.40%2.39%0.91%1.22%0.34%0.79%1.15%1.34%1.46%1.12%0.12%1.71%1.26%

According to 6 Wall Street analysts, Sarepta Therapeutics's projected average Quarter EPS for Mar 24 is $0.01, with a low estimate of $0.01 and a high estimate of $0.01. This represents a -98.37% decrease compared to SRPT previous annual EPS of $0.79 (Dec 23).

Sarepta Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.18$70.0038788.89%Buy
TERNTerns Pharmaceuticals$4.18$18.67346.65%Buy
VKTXViking Therapeutics$33.43$98.00193.15%Buy
IOVAIovance Biotherapeutics$6.07$13.50122.41%Buy
SRPTSarepta Therapeutics$115.45$184.0059.38%Buy
KRYSKrystal Biotech$156.30$210.3334.57%Buy
PTCTPTC Therapeutics$45.22$50.5011.68%Buy
MDGLMadrigal Pharmaceuticals$326.33$315.75-3.24%Buy
AKROAkero Therapeutics$54.00$50.00-7.41%Buy

SRPT Forecast FAQ

Is Sarepta Therapeutics a good buy?

Yes, according to 21 Wall Street analysts, Sarepta Therapeutics (SRPT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 16 'Buy' recommendations, accounting for 76.19% of SRPT's total ratings.

What is SRPT's price target?

Sarepta Therapeutics (SRPT) average price target is $184 with a range of $165 to $203, implying a 59.38% from its last price of $115.45. The data is based on 21 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Sarepta Therapeutics stock go up soon?

According to Wall Street analysts' prediction for SRPT stock, the company can go up by 59.38% (from the last price of $115.45 to the average price target of $184), up by 75.83% based on the highest stock price target, and up by 42.92% based on the lowest stock price target.

Can Sarepta Therapeutics stock reach $200?

SRPT's highest twelve months analyst stock price target of $203 supports the claim that Sarepta Therapeutics can reach $200 in the near future.

What are Sarepta Therapeutics's analysts' financial forecasts?

Sarepta Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.16B (high $3.56B, low $2.42B), average EBITDA is $-2.055B (high $-1.576B, low $-2.313B), average net income is $1.15B (high $1.6B, low $148.47M), average SG&A $1.65B (high $1.86B, low $1.27B), and average EPS is $11.44 (high $15.97, low $1.48). SRPT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.78B (high $4.22B, low $3.01B), average EBITDA is $-2.456B (high $-1.956B, low $-2.742B), average net income is $1.41B (high $1.62B, low $1.03B), average SG&A $1.97B (high $2.2B, low $1.57B), and average EPS is $14 (high $16.12, low $10.3).

Did the SRPT's actual financial results beat the analysts' financial forecasts?

Based on Sarepta Therapeutics's last annual report (Dec 2023), the company's revenue was $1.24B, beating the average analysts forecast of $1.17B by 6.23%. Apple's EBITDA was $-268M, missing the average prediction of $-706M by -62.04%. The company's net income was $-536M, beating the average estimation of $-413M by 29.66%. Apple's SG&A was $481.87M, missing the average forecast of $535.37M by -9.99%. Lastly, the company's EPS was $-5.8, beating the average prediction of $-4.224 by 37.30%. In terms of the last quarterly report (Dec 2023), Sarepta Therapeutics's revenue was $396.78M, beating the average analysts' forecast of $387.18M by 2.48%. The company's EBITDA was $-28.46M, missing the average prediction of $-252M by -88.70%. Sarepta Therapeutics's net income was $45.66M, beating the average estimation of $6.92M by 559.29%. The company's SG&A was $131.7M, missing the average forecast of $202.15M by -34.85%. Lastly, the company's EPS was $0.79, beating the average prediction of $0.0689 by 1045.92%